Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Dalbavancin (Dalvance) vs Oritavancin (Orbactiv / Kimyrsa)
An educational, source-based comparison of Dalbavancin (Dalvance) and Oritavancin (Orbactiv / Kimyrsa) — how each peptide works, what it's researched for, and what to know before going deeper.
Long-acting lipoglycopeptide for skin and soft tissue infections.
Semi-synthetic lipoglycopeptide that binds D-Ala-D-Ala, inhibiting Gram-positive cell wall synthesis; long terminal half-life supports single- or two-dose courses.
- Acute bacterial skin and skin structure infections (ABSSSI)
- S. aureus bacteremia (investigational)
- • FDA-approved.
- • Allows outpatient single-dose treatment.
Single-dose lipoglycopeptide for acute bacterial skin and skin structure infections.
Semisynthetic lipoglycopeptide derivative of chloroeremomycin that inhibits cell wall synthesis (transglycosylation, transpeptidation) and disrupts membrane integrity in Gram-positive bacteria including MRSA.
- Acute bacterial skin and skin structure infections (ABSSSI)
- • FDA-approved.
- • Artifactually elevates aPTT/PT for up to 48 hours; avoid unfractionated heparin for 48h.
Trial-evidence rating
Educational grade reflecting how many peer-reviewed studies and FDA actions we cite for each peptide. Not a clinical recommendation.
FDA-approved with published clinical trial data.
FDA-approved with published clinical trial data.
Study-by-study comparison
| Peptide | Study | Source | Year | Summary |
|---|---|---|---|---|
| Dalbavancin (Dalvance) | DISCOVER 1 & 2 trials | NEJM | 2014 | Non-inferior to vancomycin/linezolid for ABSSSI with simpler dosing. |
| Oritavancin (Orbactiv / Kimyrsa) | SOLO trials | NEJM | 2014 | Single dose non-inferior to 7–10 days of vancomycin in ABSSSI. |
Side-effect & safety grid
- FDA-approved.
- Allows outpatient single-dose treatment.
- FDA-approved.
- Artifactually elevates aPTT/PT for up to 48 hours; avoid unfractionated heparin for 48h.
Educational summary of considerations reported in research literature — not a complete list of adverse events. Discuss with a licensed clinician before any use.
Dalbavancin (Dalvance) vs Oritavancin (Orbactiv / Kimyrsa) — Key differences
- Class: Dalbavancin (Dalvance) is classified as Lipoglycopeptide · Infectious Disease, while Oritavancin (Orbactiv / Kimyrsa) is Lipoglycopeptide · Antibiotic.
- Primary research focus: Dalbavancin (Dalvance) — acute bacterial skin and skin structure infections (absssi); Oritavancin (Orbactiv / Kimyrsa) — acute bacterial skin and skin structure infections (absssi).
- Tag: FDA-Approved · Antibiotic vs FDA-Approved · Antibiotic.
Dalbavancin (Dalvance) — Frequently Asked Questions
Dalbavancin vs vancomycin — what are the key differences?+
Vancomycin is a first-line IV glycopeptide dosed every 8–12 hours with therapeutic drug monitoring, typically over 7–14+ days for acute bacterial skin and skin structure infections (ABSSSI). Dalbavancin is a long-acting lipoglycopeptide administered as a single 30-minute 1500 mg IV infusion (or 1000 mg followed by 500 mg one week later), leveraging a terminal half-life of ~14 days. Non-inferiority ABSSSI trials (DISCOVER 1 & 2) showed comparable clinical response versus vancomycin/linezolid comparators, with the operational advantage of avoiding indwelling IV access and inpatient stays.
Dalbavancin vs oritavancin — how do they compare?+
Both are long-acting lipoglycopeptides FDA-approved for ABSSSI caused by susceptible Gram-positive organisms including MRSA. Oritavancin is a single 1200 mg IV dose over 3 hours (or 3-dose regimen); dalbavancin is 1500 mg single dose over 30 minutes or a two-dose regimen. Half-life is longer for dalbavancin (~14 days) vs oritavancin (~10 days terminal). Oritavancin has known interference with coagulation assays (aPTT, PT/INR) for up to 48 hours; dalbavancin does not have the same interference profile.
Oritavancin vs dalbavancin — which has fewer drug interactions?+
Oritavancin is a weak inhibitor of CYP2C9 and CYP2C19 and a weak inducer of CYP3A4 and CYP2D6, and it artifactually prolongs aPTT for ~48 hours and PT/INR for ~24 hours after infusion, complicating heparin monitoring. Dalbavancin has minimal CYP interaction signal and no clinically significant coagulation-assay interference in labeled studies. For patients requiring anticoagulation monitoring, dalbavancin is often the operationally simpler choice.
Is dalbavancin as effective as vancomycin for MRSA skin infections?+
In the DISCOVER 1 and DISCOVER 2 Phase III non-inferiority trials of ABSSSI (including MRSA), dalbavancin met non-inferiority versus vancomycin followed by oral linezolid at the primary early clinical response endpoint. Regulatory approval reflects that non-inferiority. Vancomycin remains a standard first-line agent; dalbavancin is used when a long-acting single-infusion option is preferred.
Oritavancin (Orbactiv / Kimyrsa) — Frequently Asked Questions
Dalbavancin vs oritavancin — which lipoglycopeptide should be studied?+
Both are single-dose or short-course long-acting lipoglycopeptides approved for ABSSSI including MRSA. The choice in research and clinical protocols usually turns on: coagulation-assay interference (oritavancin interferes with aPTT/PT/INR for 24–48 h; dalbavancin does not), infusion duration (oritavancin 3 hours vs dalbavancin 30 minutes), and terminal half-life (dalbavancin ~14 days vs oritavancin ~10 days).
Oritavancin dalbavancin comparison — what does the SOLO/DISCOVER evidence show?+
Oritavancin was evaluated in the SOLO I and SOLO II Phase III ABSSSI trials versus IV vancomycin, meeting non-inferiority. Dalbavancin was evaluated in DISCOVER 1 and DISCOVER 2 versus vancomycin followed by oral linezolid, also meeting non-inferiority. No head-to-head Phase III trial directly compares oritavancin to dalbavancin; comparisons in the literature are indirect.